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Abstract
The tumor microenvironment plays a critical role in breast cancer progression. Here, we investigated tumor-
infiltrating lymphocytes (TILs) and associations with macrophage numbers, tumor stromal elastosis, vascular
invasion, and tumor detection mode. We performed a population-based retrospective study using data from The
Norwegian Breast Cancer Screening Program in Vestfold County (2004–2009), including 200 screen-detected
and 82 interval cancers. The number of TILs (CD45+, CD3+, CD4+, CD8+, and FOXP3+) and tumor-associated
macrophages (CD163+) was counted using immunohistochemistry on tissue microarray slides. Lymphatic and
blood vessel invasion (LVI and BVI) were recorded using D2-40 and CD31 staining, and the amount of elastosis
(high/low) was determined on regular HE-stained slides. High numbers of all TIL subsets were associated with LVI
(p ≤ 0.04 for all), and high counts of several TIL subgroups (CD8+, CD45+, and FOXP3+) were associated with
BVI (p ≤ 0.04 for all). Increased levels of all TIL subsets, except CD4+, were associated with estrogen receptor-
negative tumors (p < 0.001) and high tumor cell proliferation by Ki67 (p < 0.001). Furthermore, high levels of
all TIL subsets were associated with high macrophage counts (p < 0.001) and low-grade stromal elastosis
(p ≤ 0.02). High counts of CD3+, CD8+, and FOXP3+ TILs were associated with interval detected tumors
(p ≤ 0.04 for all). Finally, in the luminal A subgroup, high levels of CD3+ and FOXP3+ TILs were associated with
shorter recurrence-free survival, and high counts of FOXP3+ were linked to reduced breast cancer-specific sur-
vival. In conclusion, higher levels of different TIL subsets were associated with stromal features such as high mac-
rophage counts (CD163+), presence of vascular invasion, absence of stromal elastosis, as well as increased tumor
cell proliferation and interval detection mode. Our findings support a link between immune cells and vascular
invasion in more aggressive breast cancer. Notably, presence of TIL subsets showed prognostic value within the
luminal A category.
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Introduction
Mammography screening identifies a subset of breast
cancers with a better prognosis than expected based on
standard histopathologic and molecular prognostic fea-
tures [1–3]. There are challenges of overdiagnosis and
overtreatment following screening [4–7], and new bio-
markers are needed to better guide and improve
therapies toward a successful clinical outcome, and to
avoid overtreatment.
Breast tumors are composed of a heterogeneous
population of cells including both tumor cells and the
surrounding microenvironment. Stromal components
facilitate cancer progression and can be predictive
of both prognosis and treatment response [8–10].
Increased knowledge of the tumor microenvironment
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of screen-detected breast cancers is needed to possibly
explain their indolent behavior and good prognosis in
most of the cases.
Previously, we reported that deposition of abnormal
elastin material (elastosis) in breast cancer stroma is asso-
ciated with mammographic screen detection, low tumor
cell proliferation by Ki67 expression, and a favorable
patient prognosis [11]. In a subsequent study, we found
that tumor cell invasion into blood vessels strongly corre-
lates with interval detected breast cancers and a basal-
like tumor phenotype [12], as well as low stromal
elastosis. Also, tumor-associated macrophages (TAM)
expressing CD163 were related to vascular invasion,
nonluminal subtypes, and interval breast cancer [13].
Based on the importance of the tumor immune
microenvironment (TIME) in breast cancer [14–19],
the purpose of our present study was to investigate the
relationship between tumor-infiltrating lymphocytes
(TILs) and tissue macrophages with the presence of
vascular invasion and stromal elastosis in breast can-
cers stratified by detection mode, as these relationships
may be of potential prognostic value and relevant for
treatment strategies. The study was based on material




A population-based cohort of 285 patients from
Vestfold County in Eastern Norway, initially including
202 invasive screen-detected cancers and 83 invasive
interval tumors, was identified. The Norwegian Breast
Cancer Screening Program, implemented in 2004,
involves biannual mammography in the age-group
50–69 years. An interval cancer was defined as a can-
cer diagnosed between two screening sessions. Three
patients were excluded: one patient with no residual
tumor tissue for analysis, one screen-detected malig-
nant phyllodes tumor, and one patient with an interval
cancer unsuitable for further surgical treatment. Four
patients, two screening and two interval cancers, had
simultaneous tumors in both breasts. Tumors with the
worst prognostic profile, based on the Nottingham
Prognostic Index, were selected for inclusion in
the study cohort. Finally, 200 screen-detected and
82 interval cancers were included for further analyses.
Information on clinical data, tumor stage, and sur-
vival was retrieved from patient records. Last clinical
follow-up was in August 2018. Regarding primary
treatment, 204 breast resections (72%) and
78 mastectomies (28%) were performed; 218 patients
received radiation therapy (77%), 156 received endo-
crine treatment (55%), and 77 received chemotherapy
(27%); 12 patients lacked information on nonsurgical
primary treatment. Subsequent distant metastases were
observed in 42 cases (15%), and 32 patients (11%)
died of breast cancer during the follow-up period. The
study was approved by the Regional Ethics Committee
of Eastern Norway (reference #2018/1102).
Tissue specimens
Three tissue cores (diameter 1.0 mm) were extracted
from the invasive edge of tumor samples in paraffin-
embedded blocks and inserted into tissue microarray
(TMA) recipient blocks using a semi-automated preci-
sion instrument (Minicore 3 Tissue Arrayer; Alphelys,
Plaisir, France). As reported in previous studies
[13,20,21], TMA cores were available for 229 (81%)
out of 282 cases. In 40 cases (14%), TMA cores had
very limited tissue for evaluation, and whole sections
were used in these cases. In 13 cases (5%), only core
needle biopsies were available and used. Vascular
invasion, identified by using immunostaining for
CD31 and D2-40, and presence of stromal elastosis
(high/low) were determined on whole slides, and
results from previous studies were included for further
association analyses [12].
Immunohistochemistry
Immunohistochemistry was performed on 4–5 μm stan-
dard tumor tissue sections of formalin-fixed paraffin-
embedded TMAs. All slides were dewaxed with xylene/
ethanol before antigen retrieval in a pressure cooker
(Decloaking Chamber Plus, Biocare Medical, Concord,
CA, USA), or in a microwave, in Target Retrieval Solu-
tion (TRS) buffer (pH 9) (S2367; DAKO/Agilent). An
endogenous block was applied prior to incubation with
the primary antibodies to block for endogenous enzy-
matic activity. The slides were then incubated for 1 h
with mouse monoclonal CD3, CD4, CD8, CD45, and
FOXP3 antibodies (A0452 [Dako/Agilent, Santa Clara,
CA, USA], 104-R15 [Cell Marque, Darmstadt, Germany],
M7103 [Dako], M0701 [Dako], and M560044 [BD
Biosciences, San Jose, CA, USA], respectively) followed
by incubation with an appropriate HRP-En Vision
(Dako), EnVision Mouse hrp, K4001 for CD8 and
FOXP3, EnVision rabbit HRP, and K4003 for CD3 and
CD4. Primary antibodies were omitted for the negative
controls. Tissue from differentiated breast cancer types
were used as positive controls.
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Evaluation of staining
Cytoplasmic CD3, CD4, CD8, CD45, and FOXP3
staining was evaluated in a quantitative manner.
Staining was examined in the most active areas (hot-
spots), often situated in the periphery of the tumor
(Figure 1). Lymphocytes were most often observed
within stromal bands, and less often between tumor
cells. The target area was evaluated by using an eye-
piece graticule (10  10 grid-lines; 0.31  0.31 mm;
total 0.096 mm2), and the numbers of positive cells
were counted within one such area per case, similar to
what we reported previously for macrophages [13].
Interobserver variability
A total of 50 immunostained cases were examined by
two pathologists (YC and TAK), with kappa values
ranging from 0.69 to 0.88 for various lymphocyte
populations.
Immunohistochemical evaluations of CD163
staining for TAMs, D2-40 staining for lymphatic ves-
sel invasion (LVI), and CD31 staining for blood vessel
invasion (BVI) have been described previously, and
data were included for comparisons [12,13]. Evalua-
tions of HER2 status and of Ki67, estrogen receptor
(ER), and progesterone receptor (PR) staining have
also been reported [11–13].
Histopathologic data
All cases were microscopically reexamined by one of
the authors (TAK) using hematoxylin–eosin–safran
(HES)-stained sections from our previous study.
Tumors were classified as either invasive carcinoma of
Figure 1. Histologic images of TIL subsets at the tumor margin by immunohistochemistry (400). (A) HE stain, (B) CD45, (C) CD3,
(D) CD4, (E) CD8, and (F) FOXP3.
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no special type or other types. Histologic grading was
performed according to the Nottingham criteria [22].
Tumor diameter was measured microscopically in mil-
limeters, and lymph node status was included from
pathology reports. Surrogate criteria for breast cancer
molecular subtypes were applied according to the
St Gallen Consensus Conference from 2013 [23]. The
cut-off point used for ER and PR was 1% using Amer-
ican Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP) guideline recom-
mendations [24].
Elastosis can easily be recognized in standard HES
slides as a deposit of gray, fibrillary material, and the
histologic evaluation of tumor elastosis was described
in our previous paper [11]. In brief, the amount of
elastotic stroma in the tumor was evaluated, in cases
with whole tissue sections available, and was graded
semiquantitatively, from 0 to 3, using the criteria by
Shivas and Douglas [25]. In the present study, we used
data from HES-stained tissue, and elastosis was mor-
phologically divided into two categories, low or high;
low-grade cases had no or limited to moderate
elastosis (grade 0–2) and high-grade cases had exten-
sive elastosis (grade 3), as reported in our previous
study [11].
Statistical analysis
All statistical analyses were performed using IBM
SPSS Statistics, version 23.0 (IBM Corp., Armonk,
NY, USA). Two-sided P values of <0.05 were consid-
ered statistically significant. Associations between
categorical variables were assessed by Pearson’s chi-
square test. Spearman’s rank correlation test was
applied when comparing bivariate continuous variables
and Spearman’s correlation coefficients are reported.
When analyzing differences in TIL subsets between
phenotypic categories, Kruskal–Wallis test was
applied. Univariate survival analysis of time to death
due to breast cancer (disease-specific survival, DSS)
and time to recurrence for patients without metastases
at the time of diagnosis (recurrence-free survival,
RFS) were performed using the Kaplan–Meier method
(log-rank test for differences). Entry date was the time
of diagnosis. Patients who died from other causes were
censored at the date of death in the analyses of DSS.
A multivariable logistic regression analysis was
applied to assess the ability of different TIL subsets to
predict aggressive breast cancers (enter method, where
all selected variables were included in one step). For
statistical analysis, TIL scores were dichotomized;
high TIL score (upper quartile) and low TIL score
(others). A total of 282 patients were available for
survival analysis in the current study.
Results
Presence of TIL subsets in breast cancer
Figure 1 shows lymphocyte infiltration in tumor tis-
sues with sections, from the tumor margins, stained
immunohistochemically for CD3, CD4, CD8, CD45,
and FOXP3. There was very good concordance
between overall lymphocyte counts on HE-stained and
CD45-stained sections (r = 0.80, p < 0.001). Median
counts of CD3, CD4, CD8, CD45, and FOXP3 are
37, 15, 18, 42, and 4, respectively (see supplementary
material, Table S1). Cross-correlation between differ-
ent TIL subsets and tissue macrophages showed
that they are significantly related (p < 0.01) (see
supplementary material, Table S2).
High levels of TIL subsets are associated with TAM
counts, ER, HER2, Ki67, stromal elastosis, and
breast cancer detection mode
Table 1 presents the relationships between counts of
TIL subsets (CD3, CD4, CD8, CD45, and FOXP3)
and clinicopathologic features, proliferation by Ki67,
vessel invasion, CD163-positive TAMs, elastosis, and
tumor detection method, showing multiple significant
associations. High levels of all TIL subsets in hot-spot
areas (except CD4) were strongly associated with ER
negativity, HER2-positive tumors, and high tumor cell
proliferation (by Ki67). Furthermore, high levels of all
TIL subsets were associated with low stromal
elastosis. High levels of the T-cell markers CD3, CD8,
and FOXP3 were associated with interval detected
tumors.
When including all TIL subsets (CD45, CD3, CD4,
CD8, and FOXP3) in multivariable logistic regression
analyses as explanatory variables, and using histologic
grade, ER/PR/HER2 status, Ki67, BVI, LVI, CD163
TAM, elastosis, and detection method as predicted (out-
come) variables in separate regression models, we con-
sistently found that FOXP3 independently predicted
aggressive tumor features, such as ER negativity (odds
ratio [OR] 4.4, 95% CI 1.7–11.6, p = 0.003), HER2
positivity (OR 4.1, 95% CI 1.5–11.5, p = 0.007), high
Ki67 (OR 3.6, 95% CI 1.8–7.5, p = 0.001), BVI (OR
2.9, 95% CI 1.2–6.9, p = 0.015), LVI (OR 2.3, 95% CI
1.1–4.7, p = 0.025), and high CD163 TAM (OR 2.7,
95%CI 1.3–5.8, p = 0.009). In contrast, the other TIL
subsets were not independently associated with these
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Table 1. The correlation between CD3, CD4, CD8, CD45, and FOXP3 counts compared with clinicopathologic features, Ki67, vessel
invasion, CD163-positive macrophages, elastosis, and detection mode (n = 282).
CD3 CD4 CD8 CD45 FOXP3
Low High Low High Low High Low High Low High
Variable N N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Histologic type
NST 228 172 (81) 56 (81) 171 (81) 57 (81) 169 (80) 59 (84) 173 (82) 55 (79) 169 (80) 59 (84)
Other 54 41 (19) 13 (19) 41 (19) 13 (19) 43 (20) 11 (16) 55 (18) 15 (21) 43 (20) 11 (16)
p = 0.94 p = 0.88 p = 0.40 p = 0.58 p = 0.40
Tumor size (cm)
<2 214 164 (77) 50 (72) 159 (75) 55 (79) 158 (75) 56 (80) 161 (76) 53 (76) 159 (75) 55 (79)
≥2 68 49 (23) 19 (28) 53 (25) 15 (21) 54 (25) 14 (20) 51 (24) 17 (24) 53 (25) 15 (21)
p = 0.44 p = 0.97 p = 0.35 p = 0.97 p = 0.55
Histologic grade
1 76 64 (30) 12 (17) 61 (29) 15 (21) 60 (28) 16 (23) 62 (29) 14 (20) 64 (30) 12 (17)
2–3 208 149 (70) 57 (83) 151 (71) 55 (79) 157 (72) 54 (77) 155 (71) 56 (80) 148 (70) 58 (83)
p = 0.04 p = 0.23 p = 0.37 p = 0.13 p = 0.03
Lymph node
status*
Negative 187 145 (68) 42 (61) 147 (70) 40 (57) 140 (66) 47 (67) 139 (66) 48 (69) 146 (69) 41 (59)
Positive 94 67 (32) 27 (39) 64 (30) 30 (43) 71 (34) 23 (33) 72 (34) 22 (31) 66 (31) 28 (41)
p = 0.25 p = 0.05 p = 0.90 p = 0.68 p = 0.15
ER
Positive 249 198 (93) 51 (74) 190 (90) 59 (84) 197 (93) 52 (74) 195 (92) 54 (77) 200 (94) 49 (70)
Negative 33 15 (7) 18 (26) 22 (10) 11 (16) 15 (7) 18 (26) 17 (8) 16 (23) 12 (6%) 21 (30)
p < 0.001 p = 0.23 p < 0.001 p < 0.001 p < 0.001
PR
Positive 186 144 (68) 42 (61) 141 (67) 45 (64) 147 (69) 39 (56) 144 (68) 42 (60) 146 (69) 40 (57)
Negative 96 69 (32) 27 (39) 71 (33) 25 (36) 65 (31) 31 (44) 68 (32) 28 (40) 66 (31) 30 (43)
p = 0.31 p = 0.73 p = 0.04 p = 0.23 p = 0.07
HER2 status
Negative 255 197 (93) 58 (84) 192 (91) 63 (90) 196 (93) 59 (84) 197 (93) 58 (83) 200 (94) 55 (79)
Positive 27 16 (7) 11 (16) 20 (9) 7 (10) 16 (7) 11 (16) 15 (7) 12 (17) 12 (6) 15 (21)
p = 0.04 p = 0.89 p = 0.04 p = 0.01 p < 0.001
Ki67
Low 211 171 (80) 40 (58) 164 (77) 47 (63) 169 (80) 42 (60) 172 (81) 39 (56) 176 (83) 35 (50)
High 71 42 (20) 29 (42) 48 (23) 23 (33) 43 (20) 28 (40) 40 (19) 31 (44) 36 (17) 35 (50)
p < 0.001 p = 0.09 p < 0.001 p < 0.001 p < 0.001
LVI
Negative 212 169 (80) 43 (62) 166 (78) 46 (66) 167 (79) 45 (64) 168 (79) 44 (63) 171 (81) 41 (59)
Positive 70 44 (20) 26 (38) 46 (22) 24 (34) 45 (21) 25 (36) 44 (21) 26 (37) 41 (19) 29 (41)
p = 0.004 p = 0.035 p = 0.015 p = 0.006 p < 0.001
BVI
Negative 239 185 (87) 54 (78) 179 (84) 60 (86) 185 (87) 54 (77) 187 (88) 52 (74) 189 (89) 50 (71)
Positive 43 28 (13) 15 (22) 33 (16) 10 (14) 27 (13) 16 (23) 25 (12) 18 (26) 23 (11) 20 (29)
p = 0.084 p = 0.796 p = 0.041 p = 0.005 p < 0.001
CD163
Low 212 182 (85) 30 (44) 168 (79) 44 (63) 178 (84) 34 (49) 178 (84) 34 (49) 180 (85) 32 (46)
High 70 31 (15) 39 (56) 44 (21) 26 (37) 34 (16) 36 (51) 34 (16) 36 (51) 32 (15) 38 (54)
p < 0.001 p = 0.01 p < 0.001 p < 0.001 p < 0.001
Elastosis
Low 237 171 (80) 66 (96) 172 (81) 65 (93) 173 (82) 64 (91) 172 (81) 65 (93) 172 (81) 65 (93)
High 45 42 (20) 3 (4) 40 (19) 5 (7) 39 (27) 6 (9) 40 (19) 5 (7) 40 (19) 5 (7)
p = 0.002 p = 0.02 p = 0.05 p = 0.02 p = 0.02
Detection mode
Screening 200 158 (74) 42 (61) 149 (70) 51 (73) 157 (74) 43 (61) 155 (73) 45 (64) 159 (75) 41 (59)
Interval 82 55 (26) 27 (39) 63 (30) 19 (27) 55 (26) 27 (39) 57 (27) 25 (36) 53 (25) 29 (41)
p = 0.03 p = 0.68 p = 0.04 p = 0.16 p = 0.01
P values were obtained using Pearson’s chi-square test. High CD3, CD4, CD 8, CD45, and FOXP3 counts are given by the upper quartile.
n, number of cases; NST, no special type.
*One case was excluded due to missing information on lymph node status.
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clinicopathologic features, except that, in addition to
FOXP3, both CD3 and CD4 were independently associ-
ated with CD163 TAM status (OR 6.5, 95% CI 2.2–
19.3, p = 0.001; and OR 0.3, 95% CI 0.1–0.7,
p = 0.013).
High levels of TIL subsets are associated with
different categories of vascular invasion
High numbers of all TIL subsets were significantly
associated with LVI. Also, high counts of CD45+ leu-
kocytes as well as CD8+ and FOXP3+ lymphocytes
were associated with BVI (Table 1).
Table 2 shows the association between levels of
TILs and different combinations of vascular invasion:
LVI/BVI, LVI+/BVI, LVI/BVI+, and LVI
+/BVI+. All TIL subsets (except CD4) were signifi-
cantly associated with these categories of vascular
invasion, with FOXP3 displaying the strongest associ-
ation (p < 0.001). The general pattern was that most
LVI/BVI tumors (around 80%) had low numbers
of infiltrating lymphocytes, whereas a much higher
percentage (44–56%) of LVI+/BVI+ tumors were
highly infiltrated (Table 2). LVI+/BVI and LVI/
BVI+ tumors showed intermediate TIL percentages.
Thus, both LVI and BVI associated with increased
lymphocytic infiltration in tumor tissue.
High levels of TIL subsets are associated with
breast cancer molecular subgroups
There were 51% luminal A, 32% luminal B (HER2
negative), 6% luminal B (HER2 positive), 4%
HER2-type, and 7% triple-negative tumors in this
population-based cohort (Table 3). High levels of all
TIL subsets (except CD4) were significantly associ-
ated with breast cancer subtypes. Again, FOXP3
demonstrated the strongest association (p < 0.001).
In general, luminal A and luminal B HER2-negative
tumors showed on average low-grade lymphocytic
infiltration in around 80% of tumors (Table 3 and
supplementary material, Figure S1). In contrast,
around 50% of HER2-type and triple-negative
tumors showed high TIL counts. Intermediate values
were found for luminal B HER2-positive tumors
(Table 3).
Associations between TIL subsets and patient
prognosis
The median follow-up time was 138 months (range
108–168). Among the 282 patients, metastases or local
recurrence were observed at follow-up in 42 cases
(15%), and 32 patients (11%) died of breast cancer.
Univariate survival analysis of various TIL sub-
sets across all breast cancer subtypes in the whole
cohort did not reveal significant prognostic associa-
tions. Among luminal A tumors (n = 145), univari-
ate survival analysis indicated that high levels
(by upper quartile) of CD3- and FOXP3-positive
TILs were associated with reduced RFS (Figure 2),
and FOXP3 was also associated with reduced
DSS (p < 0.05).
High levels of both CD3 and FOXP3 were associated
with reduced RFS in patients who had not received
endocrine therapy (p = 0.018 and p = 0.028,
Table 2. Counts of CD3, CD4, CD8, CD45, and FOXP3 TIL subtypes according to different categories of vascular invasion (n = 282).
LVI/BVI LVI+/BVI LVI/BVI+ LVI+/BVI+
n (%) n (%) n (%) n (%) P value
Total 194 (68) 45 (16) 18 (6) 25 (10)
CD3
Low 155 (80) 30 (67) 14 (78) 14 (56) 0.028
High 39 (20) 15 (33) 4 (22) 11 (44)
CD4
Low 151 (78) 28 (62) 15 (83) 18 (72) 0.135
High 43 (22) 17 (38) 3 (17) 7 (28)
CD8
Low 154 (79) 31 (69) 13 (72) 14 (56) 0.05
High 40 (21) 14 (31) 5 (28) 11 (44)
CD45
Low 157 (91) 30 (67) 11 (61) 14 (56) 0.007
High 37 (19) 15 (33) 7 (39) 11 (44)
FOXP3
Low 159 (82) 30 (67) 12 (67) 11 (44) <0.001
High 35 (18) 15 (33) 6 (33) 14 (56)
Number of cases (n) and % within different categories of vessel invasion. P values were obtained using Pearson’s chi-square test. High CD3, CD4, CD8, CD45, and
FOXP3 counts are given by the upper quartile.
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respectively), but did not show significance in patients
who received endocrine therapy. Also, high levels of
CD3 and CD4 were associated with reduced RFS in
patients who did not undergo chemotherapy (p = 0.011
and p = 0.032, respectively), while there was no signif-
icant difference in cases with treatment. As expected,
treated and untreated cases (for both endocrine treat-
ment and chemotherapy) showed significant differences
with respect to tumor diameter, histologic grade, lymph
node status, as well as ER and PR positivity.
Discussion
Breast tumors are often infiltrated by a diverse popula-
tion of immune cells. The composition of TIL subsets
and their interaction with tumor cells might result in
either tumor regression or progression [26]. Our pre-
sent study indicates that different TIL subpopulations
are strongly related to more aggressive breast cancer
subgroups such as ER-negative or HER2-positive
tumors, and cases with high proliferation, as assessed
Table 3. Counts of CD3, CD4, CD8, CD45, and FOXP3 TIL subtypes by molecular subtype (n = 282).
Luminal A Luminal B HER2 type Triple negative
HER2 HER2+
n (%) n (%) n (%) n (%) n (%) P value
Total 145 (51) 89 (32) 18 (6) 9 (4) 21 (7)
CD3
High 29 (20) 19 (21) 6 (33) 5 (56) 10 (48) 0.009
Low 116 (80) 70 (79) 12 (67) 4 (44) 11 (52)
CD4
High 32 (22) 24 (27) 6 (33) 1 (11) 7 (33) 0.52
Low 113 (78) 65 (73) 12 (67) 8 (89) 14 (67)
CD8
High 28 (19) 20 (23) 6 (33) 5 (56) 11 (52) 0.002
Low 117 (81) 69 (77) 12 (67) 4 (44) 10 (48)
CD45
High 27 (19) 22 (25) 8 (44) 4 (44) 9 (43) 0.016
Low 118 (81) 67 (75) 10 (56) 5 (56) 12 (57)
FOXP3
High 24 (17) 19 (21) 9 (50) 6 (67) 12 (57) <0.001
Low 121 (83) 70 (79) 9 (50) 3 (33) 9 (43)
Number of cases (n) and % within molecular subtypes are given according to the St Gallen consensus criteria 2013 [23]. P values were obtained using Pearson’s
chi-square test. High CD3, CD4, CD8, CD45, and FOXP3 counts are given by the upper quartile.
Figure 2. RFS in luminal A cases related to high (upper quartile) or low (A) CD3 and (B) FOXP3 counts. Survival curves were estimated using
the Kaplan–Meier method (with log-rank test for differences). For each category, number of events/total number of cases are given.
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by Ki67 levels. Notably, among the TIL subsets,
FOXP3 represented an independent marker for predic-
tion of aggressive tumor subgroups in this series.
These findings support the notion that FOXP3 is a mas-
ter regulator in the TIME [27]. Our data are consistent
with other studies, indicating that composition of the
immune cell infiltrates represents a fundamental part of
breast cancer progression [14,26,28–31]. However, less
is known about how immune cells associate with other
components of the tumor stroma.
Here, we found that different TIL subsets were
strongly associated with TAMs and vascular invasion.
Importantly, we demonstrated that tumors with high-
grade inflammation showed increased frequency of
both LVI and BVI. Vascular invasion has been recog-
nized as a crucial step in metastasis and may indicate
disseminated disease and unfavorable prognosis
among cancer patients [32]. Both TILs and TAMs
have important roles in neoplasia and produce angio-
genic growth factors and cytokines that potentiate
tumor angiogenesis and progression [33–38]. In line
with this, TGF-β produced by macrophages and regu-
latory T cells (FOXP3+) can promote epithelial–mes-
enchymal transition in breast tumor cells and thereby
enhance tumor cell motility and intravasation [39,40].
This may support our findings of a strong relationship
between high TIL content and vascular invasion. In
particular, FOXP3-positive lymphoid cells were
strongly associated with both LVI and BVI.
We previously demonstrated that there is a strong
association between stromal elastosis and screen-
detected cancers [11]. Notably, the present study indi-
cates that high levels of TIL subsets are strongly
inversely associated with tumor elastosis, and high
counts of CD3+, CD8+, and FOXP3+ lymphocyte
subsets are also related to interval detected cancers. To
the best of our knowledge, this is the first integrated
study of the breast cancer microenvironment in rela-
tion to tumor detection mode, and with particular
attention to lymphoid cell subtypes, stromal elastosis,
and presence of vascular invasion.
Interval detected breast cancers are more often
basal-like and HER2 positive [41] and demonstrate a
stiffer collagen stroma and higher immune cell infiltra-
tion [42] in contrast to screen-detected tumors. An
absence of elastosis and higher immune cell content
may stimulate a more angiogenic tumor microenviron-
ment with increased risk of vascular invasion and
tumor spread [43,44].
In the luminal A subtype, high numbers of CD3+
and FOXP3+ cells were associated with reduced RFS,
and FOXP3+ cells from the tumor margins were also
related to reduced DSS. In general, lower numbers of
CD3+ lymphocytes are usually associated with poorer
prognosis due to a suppressed immune response, and
FOXP3 is known to suppress antitumor responses
and facilitate cancer progression [45]. In contrast,
higher CD3+ lymphocyte numbers were associated
with reduced RFS in our study. Although our findings
on FOXP3 are consistent with previous work [46–48],
the data on CD3 might be controversial. Still, our
observations are in line with a recent report in which
the authors found that high T lymphocyte and Treg
infiltration in primary breast cancer correlated with
poor prognostic factors and shorter survival [49].
The role of TILs, especially focusing on CD8 and
FOXP3 as prognostic markers within molecular sub-
types, has been evaluated in several studies, with
particular attention paid to HER2-positive and triple-
negative breast cancer patients [50–58]. In contrast,
luminal tumors have been less well studied. Recently,
a few publications have focused on luminal
HER2-negative tumors, without finding significant
prognostic signals related to TILs [18,59], although
the methods used are somewhat different from our
study. These reports presented the total number of
TILs in HE-stained sections, without differentiating
between TIL subsets. In contrast, a meta-analysis from
2017 suggested that high FOXP3 levels predicted a
poorer prognosis in ER-positive breast cancer [60],
and this observation is in agreement with our findings
of reduced survival associated with high levels of
FOXP3 within the luminal A subgroup. Furthermore,
a study from 2019 examined TIL composition and the
phosphatidylinositol 3-kinase pathway in luminal
breast cancer. It was suggested that high levels of CD8
+ lymphocytes were observed in PIK3CA-mutated
tumors, and that these patients were more likely to
experience disease recurrence [61]. Further validation
of the prognostic value of TIL subsets is needed to
improve prognostication and potential treatment strati-
fication, and to avoid overtreatment in luminal breast
cancer.
Although several previous studies have focused
on the significance of TIL subsets in breast cancer,
methods for evaluation were different among these
investigations [62,63]. Standardization of methods
for scoring of TILs is still a key issue. A limitation
in our study was the measurement of TILs (CD3,
CD4, CD8, CD45, and FOXP3) and macrophages
(CD163) by immunohistochemistry on TMA sec-
tions. Using TMAs might underestimate the levels
due to tumor heterogeneity and limited sampling.
To reduce this potential confounding factor, three
cores were extracted from the invasive edge of the
tumor (diameter 1.0 mm). Furthermore,
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immunohistochemical staining of CD4 might also
be positive on macrophages and dendritic cells,
potentially influencing CD4 cell counts, although
cell morphology was assessed during counting to
minimize this bias.
In summary, our study on breast cancer indicates
associations between high levels of different TIL sub-
types and TAM levels, vascular invasion (LVI and
BVI), absence of stromal elastosis, tumor cell prolifer-
ation, and interval detection mode. Our findings sug-
gest an importance of tumor microenvironment
factors, and interactions between them, for progression
of breast cancer subgroups. Notably, the presence of
FOXP3+ lymphoid cells was strongly associated with
most factors studied, and was also prognostic within
the low-grade luminal A category. The interplay
between cancer cells and their microenvironment to
influence cancer progression is a challenging and
extremely complicated process, which needs further
investigation.
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